OncoSil Medical Files for FDA Approval
Filed with ASX · · 3 pages · English
Summary by 6ix AI
OncoSil Medical Ltd has filed for FDA approval of its OncoSil™ device, completing the next step in the Humanitarian Device Exemption application process. The application is now under review by the FDA, which is expected to complete its assessment within a specified timeframe. If approved, the OncoSil™ device would be the first FDA-approved Class III medical device for treating distal cholangiocarcinoma in the United States. This marks a significant milestone for OncoSil Medical, potentially establishing its first commercial presence in the U.S. market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from OncoSil Medical
- OncoSil Selected for Major European Pancreatic Cancer Study
- OncoSil progresses HDE with US FDA
- OncoSil Medical Receives TGA Approval in Australia
- Security Class Reinstatement to Quotation - OSLOE
- Security Class Suspension from Quotation
Later from OncoSil Medical
- OncoSil Medical Completes Manufacturing Validation
- Quarterly Activities/Appendix 4C Cash Flow Report
- OncoSil Receives FDA Approval for Distal Cholangiocarcinoma
- Investor Webinar Presentation
- Application for quotation of securities - OSL
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical